diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5947diaendo-5947Research ArticleСтатьиArticlesАнтигипертензивная терапия и риск развития сахарного диабетаAntigipertenzivnaya terapiya i risk razvitiya sakharnogo diabetaБарановаЕ ИBaranovaE Iinfo@endojournals.ruБольшаковаО ОBol'shakovaO Oinfo@endojournals.ruСанкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаРоссияSaint-Petersburg State Medical University n.a. I.P.PavlovRussian Federation200815032008111№1 (2008)5560Copyright © Баранова Е.И., Большакова О.О., 20082008Баранова Е.И., Большакова О.О.Baranova E.I., Bol'shakova O.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5947

Анализ результатов Фремингемского исследования продемонстрировал, что у 15?18% больных, страдающих артериальной гипертензией (АГ), выявлено нарушение толерантности к глюкозе. У пациентов, не получающих терапию по поводу артериальной гипертензии, отмечается более высокая частота развития сахарного диабета по сравнению с лицами, имеющими нормальный уровень артериального давления. Антигипертензивные препараты при длительном применении могут оказывать влияние на метаболизм глюкозы, влияя на чувствительность к инсулину и/или на секрецию инсулина, и увеличивать риск развития сахарного диабета, особенно у пациентов высокого риска (больных с метаболическим синдромом, с нарушенной толерантностью к глюкозе и с абдоминальным ожирением).

сахарный диабетангтигипертензивная терапияартериальная гипертензияReferencesKannel W.B., Wilson P.W., Zhang T.J. The epidemiology of impared glucose tolerance and hypertension // Am. Heart J. - 1991. - Vol.121. - P. 1268-1273.Kannel W.B., Wilson P.W., Zhang T.J. The epidemiology of impared glucose tolerance and hypertension // Am. Heart J. - 1991. - Vol.121. - P. 1268-1273.Waeber B., Feihl F., Ruilope L. Diabetes and hypertension// Blood Press. - 2001. - Vol.10. - P.311-321.Waeber B., Feihl F., Ruilope L. Diabetes and hypertension// Blood Press. - 2001. - Vol.10. - P.311-321.Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects// Hypertension. - 2004. - Vol.43. - P.963-969.Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects// Hypertension. - 2004. - Vol.43. - P.963-969.Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial // Diabetes Care. - 1993. - Vol.16. - P.434-444.Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial // Diabetes Care. - 1993. - Vol.16. - P.434-444.Guidelines on diabetes, pre-diabetes, and cardiovascular disease/ The Task Force on Diabetes and Cardiovascular Disease of European Society of Cardiol-ogy and of the European Asscociation for the Study of Diabetes// Eur. Heart J. - 2007 (Suppl). - Vol. 9. - P.C3-C74.Guidelines on diabetes, pre-diabetes, and cardiovascular disease/ The Task Force on Diabetes and Cardiovascular Disease of European Society of Cardiol-ogy and of the European Asscociation for the Study of Diabetes// Eur. Heart J. - 2007 (Suppl). - Vol. 9. - P.C3-C74.Guidelines for the Management of Arterial Hypertension/ The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)//J Hypertens - 2007. - Vol. 25. - P 1105-1187.Guidelines for the Management of Arterial Hypertension/ The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)//J Hypertens - 2007. - Vol. 25. - P 1105-1187.Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of cardiology (ESC) European Association for the Study of Diabetes (EASD)//Eur. Heart J. - 2007. - Vol.26. - P.88-136.Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of cardiology (ESC) European Association for the Study of Diabetes (EASD)//Eur. Heart J. - 2007. - Vol.26. - P.88-136.WHO. Diabetes mellitus. Report of a WHO study group. Geneva: World Health Organanization Technical Report Series, №. 727. 1985. - P. 1-113.WHO. Diabetes mellitus. Report of a WHO study group. Geneva: World Health Organanization Technical Report Series, №. 727. 1985. - P. 1-113.Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation// Diabet. Med. - 1998. - Vol.15. - P.539-553.Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation// Diabet. Med. - 1998. - Vol.15. - P.539-553.Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol// Lancet. - 2002. - Vol.359. - P.995-1003.Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol// Lancet. - 2002. - Vol.359. - P.995-1003.Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al., for the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al., for the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients The Heart Outcomes Prevention Evaluation Study Investigators// N. Engl. J. Med. - 2000. - Vol.342. - P.145-153.Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients The Heart Outcomes Prevention Evaluation Study Investigators// N. Engl. J. Med. - 2000. - Vol.342. - P.145-153.Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin convert-ing enzyme (ACE) inhibition// J. Cell Physiol. - 2003. - Vol.196. - P.171-179.Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin convert-ing enzyme (ACE) inhibition// J. Cell Physiol. - 2003. - Vol.196. - P.171-179.Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle// Metabolism. - 1996. - Vol.45. - P.535-541.Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle// Metabolism. - 1996. - Vol.45. - P.535-541.Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin-angiotensinaldosterone system: influence of ACE inhibition// J. Cardiovasc. Pharmacol. - 1994. - Vol.24 (Suppl 3). - P.S61-S69.Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin-angiotensinaldosterone system: influence of ACE inhibition// J. Cardiovasc. Pharmacol. - 1994. - Vol.24 (Suppl 3). - P.S61-S69.Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes// Endocrinol. Metab. Clin. North Am. - 2005. - Vol.34. - P.155-197.Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes// Endocrinol. Metab. Clin. North Am. - 2005. - Vol.34. - P.155-197.Mancia G., Grassi G., Zanchetti A. New-onset diabetes and antihypertensive drugs// J. Hypertens. - 2006. - Vol.24. - P.3-10.Mancia G., Grassi G., Zanchetti A. New-onset diabetes and antihypertensive drugs// J. Hypertens. - 2006. - Vol.24. - P.3-10.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to an-giotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart At-tack Trial (ALLHAT)// JAMA. - 2002. Vol.288. - P.2981-2997.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to an-giotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart At-tack Trial (ALLHAT)// JAMA. - 2002. Vol.288. - P.2981-2997.Conn J.W. Hypertension, the potassium ion and impaired carbohydrate tolerance// N. Engl. J. Med. - 1965. - Vol.273. - P.1135-1143.Conn J.W. Hypertension, the potassium ion and impaired carbohydrate tolerance// N. Engl. J. Med. - 1965. - Vol.273. - P.1135-1143.Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM// Am. J. Hypertens. - 1995. - Vol.8. - P.276-281.Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM// Am. J. Hypertens. - 1995. - Vol.8. - P.276-281.Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905-912.Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905-912.Bangalore S., Messerli F.H., Kostis J.B., Pepine C.J. Cardiovascular protection using beta-blockers// J. Am. Coll. Cardiol. - 2007. - Vol.50. - P.563-572.Bangalore S., Messerli F.H., Kostis J.B., Pepine C.J. Cardiovascular protection using beta-blockers// J. Am. Coll. Cardiol. - 2007. - Vol.50. - P.563-572.Koletsky R.J., Velliquette R.A., Ernsberger P. The role of I(1)-imidazoline re-ceptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X// Ann. N.Y. Acad Sci. - 2003. - Vol.1009. - P.251-561.Koletsky R.J., Velliquette R.A., Ernsberger P. The role of I(1)-imidazoline re-ceptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X// Ann. N.Y. Acad Sci. - 2003. - Vol.1009. - P.251-561.Mitrovic V., Patyna W., Huting J. et al. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension// Cardiovasc. Drugs Ther. - 1991. - Vol.5. - P.967-972.Mitrovic V., Patyna W., Huting J. et al. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension// Cardiovasc. Drugs Ther. - 1991. - Vol.5. - P.967-972.Ernsberger P. et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rats (SHROB)// J Pharmacol Exp Ther. - 1999. - Vol.288. - P.139-147.Ernsberger P. et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rats (SHROB)// J Pharmacol Exp Ther. - 1999. - Vol.288. - P.139-147.Scherrer U. et al. Body fat and sympathetic nerve activity// Cardiovasc Drug Ther. - 1996. - Vol.10 (suppl. 1). - P.215-222.Scherrer U. et al. Body fat and sympathetic nerve activity// Cardiovasc Drug Ther. - 1996. - Vol.10 (suppl. 1). - P.215-222.Chazova I., Almazov V.A., Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin// Diabetes Obes. Metab. - 2006. - Vol.8. - P.456-465.Chazova I., Almazov V.A., Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin// Diabetes Obes. Metab. - 2006. - Vol.8. - P.456-465.Landsberg L. Diabetes, obesity and hypertension: role of insulin and the sympahtetic nervous system// Cardiovasc Risk Factors. - 1993. - Vol.3. - P.153-158.Landsberg L. Diabetes, obesity and hypertension: role of insulin and the sympahtetic nervous system// Cardiovasc Risk Factors. - 1993. - Vol.3. - P.153-158.Rocchini AP, Moorhead CP, Deremer S, Bondi D. Pathogenesis of weightrelated pressure changes in blood pressure in dogs// Hypertension. - 1989. - Vol.13. - P. 922-928.Rocchini AP, Moorhead CP, Deremer S, Bondi D. Pathogenesis of weightrelated pressure changes in blood pressure in dogs// Hypertension. - 1989. - Vol.13. - P. 922-928.Jacob S., Kimm H.J., Rett K., Helsberg K., Haring H.-U., Godicke J. Сравнение эффективности применения моксонидина и метопролола у пациентов с артериальной гипертонией и сахарным диабетом 2 типа (влияние на артериальное давление и метаболические параметры)// Обзоры клинической кардиологии. - 2007. - №10. - С.16-25.Jacob S., Kimm H.J., Rett K., Helsberg K., Haring H.-U., Godicke J. Сравнение эффективности применения моксонидина и метопролола у пациентов с артериальной гипертонией и сахарным диабетом 2 типа (влияние на артериальное давление и метаболические параметры)// Обзоры клинической кардиологии. - 2007. - №10. - С.16-25.Ruggenenti P., Fassi A., Ilieva A.P. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1941-1951.Ruggenenti P., Fassi A., Ilieva A.P. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1941-1951.Opie L.H., Schall R. Old antihypertensives and new diabetes // J. Hypertens. - 2004. - V.22. - P. 1453-1458.Opie L.H., Schall R. Old antihypertensives and new diabetes // J. Hypertens. - 2004. - V.22. - P. 1453-1458.

The authors declare that there are no conflicts of interest present.